Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MMP3 | P08254 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446777 | 0.67 | ALDH1A1 (0.36) | LMNAL3MBTL1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL464694 | 0.64 | ALDH1A1 (0.43) | LMNAL3MBTL1ALDH1A1SMN1; SMN2HSP90AA1 | |
| SCHEMBL10049995 | 0.62 | HSP90AA1 (0.51) | LMNAL3MBTL1ALDH1A1SMN1; SMN2HSP90AA1 | |
| SCHEMBL13762631 | 0.60 | MMP3 (0.57) | LMNAALDH1A1MMP3SMN1; SMN2HSP90AA1 | |
| SCHEMBL6694830 | 0.59 | LMNA (1.00) | LMNAL3MBTL1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL10049989 | 0.58 | HSP90AA1 (0.63) | LMNAL3MBTL1ALDH1A1SMN1; SMN2HSP90AA1 | |
| SCHEMBL9294461 | 0.58 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2AHPGDMAPT | |
| SCHEMBL11810689 | 0.57 | L3MBTL1 (0.67) | LMNAL3MBTL1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL2810979 | 0.56 | CA2 (0.39) | LMNAL3MBTL1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL11684410 | 0.56 | L3MBTL1 (0.54) | LMNAL3MBTL1ALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680100-B2 | Sulfonylhydrazide compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120065206-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065206-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | PKD1, PKD2, PCNA | LMNA 2213/4885L3MBTL1 4705/4885ALDH1A1 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.